采用抗胸腺细胞球蛋白(atg)或抗淋巴细胞球蛋白(ALG)免疫疗法是不适宜于骨髓移植患儿的主要治疗方法。
Immunotherapy with either antithymocyte globulin (ATG) or antilymphocyte globulin (ALG) is the primary treatment for those children not candidates for bone marrow transplant.
目的探讨低剂量、短疗程的抗胸腺细胞球蛋白(ATG)治疗肾移植后早期激素耐受性排斥反应的疗效。
AIM To explore the effect of low-dose and short-term antithymocyte globulin(ATG) in treatment of early steroid-resistant rejection after renal transplantation.
同胞捐赠者的造血干细胞移植之前的预处理方案中使用抗胸腺细胞球蛋白一直是有争议的。
The use of antithymocyte globulin in a conditioning regimen prior to hematopoietic stem cell transplantation with a sibling donor has been controversial.
应用推荐